Valuation: Stoke Therapeutics, Inc.

Market Cap 1.82B 1.57B 1.49B 1.35B 2.53B 174B 2.55B 17.75B 6.83B 88.35B 6.82B 6.67B 282B P/E 2026 *
-7.76x
P/E 2027 * -7.83x
Enterprise Value 1.61B 1.4B 1.32B 1.2B 2.24B 155B 2.26B 15.76B 6.06B 78.42B 6.06B 5.92B 250B EV / Sales 2026 *
50.3x
EV / Sales 2027 * 35.1x
Free-Float
96.32%
Yield 2026 *
-
Yield 2027 * -
1 day-4.90%
1 week-6.32%
Current month-9.78%
1 month-9.98%
3 months-6.17%
6 months-15.19%
Current year-11.31%
1 week 27.82
Extreme 27.82
30.16
1 month 27.82
Extreme 27.82
33.94
Current year 25.21
Extreme 25.21
40.22
1 year 20.32
Extreme 20.32
40.22
3 years 3.35
Extreme 3.35
40.22
5 years 3.35
Extreme 3.35
40.22
10 years 3.35
Extreme 3.35
71.58
Manager TitleAgeSince
Chief Executive Officer 60 19/03/2025
Chief Tech/Sci/R&D Officer 54 01/06/2014
Director of Finance/CFO 49 07/05/2024
Director TitleAgeSince
Chairman 65 01/07/2015
Director/Board Member 67 01/06/2014
Director/Board Member 72 01/09/2015
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 A Sell

Chief Technology Officer

-5,545 0.0094%
8/18/26 A Sell

Chief Technology Officer

-4,767 0.0081%
8/18/26 A Sell

Director

-12,567 0.0212%
Change 5-day change 1-year change 3-year change Capi.($)
-4.90%-6.32%+20.30%+465.26% 1.82B
+0.06%-3.38%-1.83%+8.00% 45.81B
-0.12%-1.19%+343.42%+545.03% 43.91B
+1.51%+4.04%+45.01%+27.38% 44.39B
-2.07%-1.42%+4.28%+72.97% 39.4B
-0.73%-3.06%+9.63%+38.92% 31.26B
-9.49%-11.23% - - 15.75B
+4.21%+5.01%+24.99%+121.62% 17.32B
-0.35%+3.52%+17.24%+33.48% 14.73B
-0.08%-2.81%+79.24%+31.27% 13.03B
Average -1.17%-1.71%+60.25%+149.32% 26.74B
Weighted average by Cap. -0.48%-1.26%+76.37%+132.95%

Financials

2026 *2027 *
Net sales 32.02M 27.74M 26.23M 23.75M 44.57M 3.07B 44.9M 313M 120M 1.56B 120M 118M 4.97B 44.83M 38.83M 36.72M 33.24M 62.39M 4.3B 62.86M 438M 169M 2.18B 168M 165M 6.95B
Net income -241M -208M -197M -178M -335M -23.09B -337M -2.35B -905M -11.71B -904M -884M -37.33B -261M -226M -214M -194M -364M -25.06B -366M -2.55B -982M -12.71B -981M -960M -40.53B
Net Debt -204M -177M -167M -151M -284M -19.59B -286M -2B -768M -9.93B -767M -750M -31.68B -242M -210M -198M -180M -337M -23.22B -339M -2.37B -910M -11.77B -909M -889M -37.55B
Logo Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-001), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.
Employees
170
Date Price Change Volume
15/09/26 $28.15 -4.90% 1,089,940
14/09/26 $29.60 +1.96% 500,366
11/09/26 $29.03 -1.06% 587,515
10/09/26 $29.34 -1.94% 421,296
09/09/26 $29.92 -0.43% 666,267
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
28.15USD
Average target price
46.46USD
Spread / Average Target
+65.05%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. STOK Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!